Julio Prieto Montalvo

Dr. Julio Prieto Montalvo


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2025 in Schizophrenia
Verified
Journal Article
Open access
PDF file
DMDaniel H. Mathalon
Daniel H. Mathalon
SNSpero Nicholas
Spero Nicholas
BRBrian J. Roach
Brian J. Roach
TBTashrif Billah
Tashrif Billah
SLSuzie Lavoie
Suzie Lavoie
GLGregory A. Light
Gregory A. Light
Individuals at clinical high risk for psychosis (CHR) have variable clinical outcomes and low conversion rates, limiting development of novel and personalized treatments. Moreover, given risks of antipsychotic drugs, safer effective medications for CHR individuals are needed. The Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) Program was launched to address this need. Based on past CHR and schizophrenia studies, AMP SCZ assessed electroencephalography (EEG)-based event-related potential (ERP), event-related oscillation (ERO), and resting EEG power spectral density (PSD) measures, including mismatch negativity (MMN), auditory and visual P300 to target (P3b) and novel (P3a) stimuli, 40-Hz auditory steady state response, and resting EEG PSD for traditional frequency bands (eyes open/closed). Here, in an interim analysis of AMP SCZ EEG measures, we assess test-retest reliability and stability over sessions (baseline, month-2 follow-up) in CHR (n = 654) and community control (CON; n = 87) participants. Reliability was calculated as Generalizability (G)-coefficients, and changes over session were assessed with paired t-tests. G-coefficients were generally good to excellent in both groups (CHR: mean = 0.72, range = 0.49–0.85; CON: mean = 0.71, range = 0.44–0.89). Measure magnitudes significantly (p < 0.001) decreased over session (MMN, auditory and visual target P3b, visual novel P3a, 40-Hz ASSR) and/or over runs within sessions (MMN, auditory/visual novel P3a and target P3b), consistent with habituation effects. Despite these small systematic habituation effects, test-retest reliabilities of the AMP SCZ EEG-based measures are sufficiently strong to support their use in CHR studies as potential predictors of clinical outcomes, markers of illness progression, and/or target engagement or secondary outcome measures in controlled clinical trials. Watch Dr Daniel H. Mathalon discuss their work and this article: https://vimeo.com/1066564687.

1 March 2021 in Revue Neurologique
Verified
Journal Article
Closed access
AAA.L. Alungulese
A.L. Alungulese
JLJ.A. Guzmán-De-Villoria Lebiedziejewsi
J.A. Guzmán-De-Villoria Lebiedziejewsi
JMJulio Prieto Montalvo
Julio Prieto Montalvo

23 September 2026 in Molecular Autism
Verified
Journal Article
Open access
PDF file
EBEleonora Broggi
Eleonora Broggi
TBTeresa Del Bianco
Teresa Del Bianco
RHRianne Haartsen
Rianne Haartsen
ACAntonia San José Cáceres
Antonia San José Cáceres
LCLaura Colomar
Laura Colomar
IRInge Winter-Van Rossum
Inge Winter-Van Rossum
Background: Autism clinical trials are hampered by the lack of treatment response biomarkers. We investigated N170 latency (N170L), an electrophysiological (EEG) index of face processing speed, as a candidate biomarker of treatment response to arbaclofen, a selective GABA-B agonist. We previously reported that N170L is, on average, slower in autism, and linked to genetic, neurobiological, and socialisation variability. Here, we explored whether: 1) arbaclofen modulates N170L over 16 weeks; 2) baseline N170L or change in N170L (ΔN170L) predicts change in social functioning over 16 weeks; 3) N170L improves estimation of treatment effects. Methods: In this phase II, randomised, double-blind, placebo-controlled trial, 122 autistic children and adolescents (aged 5–17) were administered arbaclofen ( N = 59) or placebo ( N = 63) for 16 weeks. N170L was extracted from EEG recorded during passive viewing of upright faces at week 0 (baseline; N = 96) and week 16 (endpoint; N = 87). Treatment efficacy on social functioning was assessed using the Socialization domain of the Vineland Adaptive Behavior Scales, 3rd edition, alongside parent/clinician-rated outcomes. Pre-registered hypotheses were tested using linear mixed-effects models. Results: N170L remained stable over 16 weeks, with no significant change overall ( p = 0.371), and arbaclofen did not modulate N170L relative to placebo ( p = 0.737). Baseline N170L did not predict change in any clinical outcome (all p > 0.472). However, individual differences in ΔN170L were associated with selected clinical outcomes. In the placebo group, slowing of N170L was associated with greater peer interaction difficulties ( p = 0.032) and improved global clinical status ( p = 0.002). For social cognition, the associations differed by treatment group ( p = 0.022), with N170L slowing linked to greater social-cognitive difficulties under placebo, but fewer social-cognitive difficulties under arbaclofen. Baseline N170L and ΔN170L minimally impacted treatment effects estimation as covariates. Limitations: Interpretation of N170L–clinical associations is limited by short trial duration and reliance on broad, informant-based social measures that, while clinically meaningful, indirectly index face-processing abilities. Conclusions: N170L showed limited utility as treatment response biomarker in this trial, although its relevance in other therapeutic contexts remains to be determined. We also demonstrated feasibility of integrating EEG into multi-site autism clinical trials, supporting future biomarker-enabled pharmacological research. Trial registration: ClinicalTrials.gov, NCT03682978. Registered September 25, 2018.

14 January 2026 in NeuroSci
Verified
Journal Article
Open access
PDF file
RGRoberto García-Leal
Roberto García-Leal
JMJulio Prieto Montalvo
Julio Prieto Montalvo
JVJuan Guzman de Villoria
Juan Guzman de Villoria
Massimiliano ZaninMassimiliano Zanin
Massimiliano Zanin
EREstrella Rausell
Estrella Rausell
Hand representation maps of the primate primary motor (M1) and somatosensory (SI) cortices exhibit plasticity, with their spatial extent modifiable through training. While activation and map enlargement during tapping tasks are well documented, the directionality of information flow between these regions remains unclear. We applied Information Imbalance Gain Causality (IIG) to examine the propagation and temporal dynamic of BOLD activity among Area 4 (precentral gyrus), Area 3a (fundus of the central sulcus), and SI areas (postcentral gyrus). Data were collected from both hemispheres of nine participants performing alternating right–left hand finger tapping inside a 1.5T fMRI scan. The results revealed strong information flow from both the precentral and postcentral gyri toward the sulcus during tapping task, with weaker bidirectional exchange between the gyri. When not engaged in tapping, both gyri communicated with each other and the sulcus. During active tapping, flow bypassed the sulcus, favoring a more direct postcentral to precentral way. Overtime, postcentral to sulcus influence strengthened during non task periods, but diminished during tapping. These findings suggest that M1, Area 3a, and SI areas form a dynamic network that supports rapid learning processing, where Area 3a of the sulcus may contribute to maintaining representational plasticity during complex tapping tasks.